Your browser doesn't support javascript.
loading
Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents.
Li, Xiaxin; Brazauskas, Ruta; Wang, Zhiwei; Al-Seraihy, Amal; Baker, K Scott; Cahn, Jean-Yves; Frangoul, Haydar A; Gajewski, James L; Hale, Gregory A; Hsu, Jack W; Kamble, Rammurti T; Lazarus, Hillard M; Marks, David I; Maziarz, Richard T; Savani, Bipin N; Shah, Ami J; Shah, Nirali; Sorror, Mohamed L; Wood, William A; Majhail, Navneet S.
Afiliação
  • Li X; Banner Children's Specialists Pediatric Hematology/Oncology, Banner Health, Mesa, Arizona.
  • Brazauskas R; Division of Biostatistics, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Wang Z; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Al-Seraihy A; Hematopoietic Stem Cell Transplantation Program, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Baker KS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Cahn JY; Clinique Universitaire d'Hematologie, University Hospital, Grenoble, France.
  • Frangoul HA; Pediatric Blood and Marrow Transplant Program, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Gajewski JL; Bone Marrow & Stem Cell Transplant Program, Oregon Health and Science University, Portland, Oregon.
  • Hale GA; Division of Hematology and Oncology, All Children's Hospital, St. Petersburg, Florida.
  • Hsu JW; Division of Hematology & Oncology, Shands HealthCare and University of Florida, Gainesville, Florida.
  • Kamble RT; Section of Hematology-Oncology, Baylor College of Medicine Center for Cell and Gene Therapy, Houston, Texas.
  • Lazarus HM; Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio.
  • Marks DI; BMT Unit, Bristol Children's Hospital, Bristol, United Kingdom.
  • Maziarz RT; Bone Marrow & Stem Cell Transplant Program, Oregon Health and Science University, Portland, Oregon.
  • Savani BN; Pediatric Blood and Marrow Transplant Program, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Shah AJ; Division of Hematology/Oncology, Department of Pediatrics, Mattel Children's Hospital at UCLA, Los Angeles, California.
  • Shah N; National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Sorror ML; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
  • Wood WA; Division of Hematology and Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina.
  • Majhail NS; Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota; Blood & Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio. Electronic address: nmajhail@nmdp.org.
Biol Blood Marrow Transplant ; 20(4): 587-92, 2014 Apr.
Article em En | MEDLINE | ID: mdl-24388803
We conducted a nested case-control study within a cohort of 6244 patients to assess risk factors for avascular necrosis (AVN) of bone in children and adolescents after allogeneic transplantation. Eligible patients were ≤21 years of age, received their first allogeneic transplant between 1990 and 2008 in the United States, and had survived ≥ 6 months from transplantation. Overall, 160 patients with AVN and 478 control subjects matched by year of transplant, length of follow-up and transplant center were identified. Patients and control subjects were confirmed via central review of radiology, pathology, and/or surgical procedure reports. Median time from transplant to diagnosis of AVN was 14 months. On conditional logistic regression, increasing age at transplant (≥5 years), female gender, and chronic graft-versus-host disease (GVHD) were significantly associated with increased risks of AVN. Compared with patients receiving myeloablative regimens for malignant diseases, lower risks of AVN were seen in patients with nonmalignant diseases and those who had received reduced-intensity conditioning regimens for malignant diseases. Children at high risk for AVN include those within the age group where rapid bone growth occurs as well as those who experience exposure to myeloablative conditioning regimens and immunosuppression after hematopoietic cell transplantation for the treatment of GVHD. More research is needed to determine whether screening strategies specifically for patients at high risk for developing AVN with early interventions may mitigate the morbidity associated with this complication.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteonecrose / Osso e Ossos / Transplante de Células-Tronco Hematopoéticas / Neoplasias Hematológicas / Condicionamento Pré-Transplante Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteonecrose / Osso e Ossos / Transplante de Células-Tronco Hematopoéticas / Neoplasias Hematológicas / Condicionamento Pré-Transplante Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2014 Tipo de documento: Article